Sign in to view content

Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy With Intravitreal Aflibercept Injection: 52-Week Results From PANORAMA

W. Lloyd Clark, MD, FASRS

Video
Published 2019

W. Lloyd Clark, MD

Diabetic Retinopathy Part I Symposium

Related

Differences in Intravitreal Silicone Oil Following Multiple Bevacizumab, Ranibizumab, and Aflibercept Injections
John T. Thompson, MD
Annual Meeting Talks
2019
Association of Ultra-Widefield Fluorescein Angiography-identified Retinal Nonperfusion With Risk of Diabetic Retinopathy Worsening Over Time
Paolo Antonio S. Silva, MD
Annual Meeting Talks
2022
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more